PRMT5 Targeted Therapies Market By Drug Type (Small Molecule Inhibitors, Allosteric Inhibitors, Protein Degraders); By Application (NSCLC, Glioblastoma, Pancreatic Cancer, Mantle Cell Lymphoma, AML, MDS); By Route of Administration (Oral, Intravenous); By End User (Academic Cancer Centers, Oncology Clinics, Community Hospitals, CROs); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global PRMT5 Targeted Therapies Market is poised to expand at a robust CAGR of 28.4%, valued at approximately USD 412 million in 2024, and projected to reach around USD 1.92 billion by 2030, according to Strategic Market Research. estimates based on current pipeline and investment trajectories. This market is gaining fast traction as PRMT5 (protein arginine methyltransferase 5) emerges as a validated target in both rare and aggressive cancers — particularly those with MTAP-deletion and splicing abnormalities.

 

PRMT5 plays a central role in the epigenetic regulation of gene expression. It’s especially critical in the symmetric dimethylation of arginine residues on histones and other cellular proteins. Aberrant activity of PRMT5 has been implicated in a wide range of malignancies including glioblastoma, non-small cell lung cancer (NSCLC), mantle cell lymphoma, and pancreatic ductal adenocarcinoma. The therapeutic strategy? Block PRMT5’s enzymatic activity to restore cellular balance and selectively kill cancer cells — particularly those that rely on PRMT5 due to MTAP loss or synthetic lethality pathways.

 

The strategic importance of this market in 2024 and beyond is fueled by a few critical forces converging:

• A clear biomarker-driven patient stratification model (MTAP-deletion, spliceosome mutations)

• Growing precision oncology infrastructure supporting biomarker testing

• Increasing FDA flexibility for orphan drug designations and breakthrough therapy approvals

• Deepening collaboration between biopharma firms and academic institutions for early-phase trials

Unlike broader oncology markets, PRMT5 therapeutics sit at the intersection of epigenetic control, RNA processing, and synthetic lethality — making them a high-priority focus for R&D-heavy companies. Several assets are now in Phase I/II clinical trials, with promising monotherapy and combination data (especially with immune checkpoint inhibitors and DNA damage repair agents).

 

The stakeholder map is evolving quickly:

• Biotech innovators like Storm Therapeutics, Prelude Therapeutics, and Epizyme are actively developing small molecule inhibitors and RNA-modifying agents targeting PRMT5.

• Big Pharma players like Roche, GSK, and Merck are layering PRMT5 into broader oncology portfolios, often through acquisitions or licensing deals.

• Clinical oncologists are exploring PRMT5 inhibitors in mutation-enriched patient groups who have limited response to conventional chemo or immunotherapy.

• Investors are watching closely as more preclinical data transitions into first-in-human results — often a leading signal in oncology deal -making.

The key difference in 2024? PRMT5 isn’t being pursued as a general cytotoxic. It’s a biomarker-matched therapy — much like PARP inhibitors were a decade ago. That’s raising both the scientific bar and the commercial opportunity.

 

To be honest, PRMT5-targeted therapy isn’t a “broad-spectrum” play. It’s about depth, not width. But in the right patients, the impact could be profound. And the first-to-market advantage here is going to be massive — not just for monotherapy but as a backbone in next-gen combination regimens.

 

Market Segmentation And Forecast Scope

The PRMT5 targeted therapies market is still in its clinical-phase lifecycle, but segmentation is already taking shape around how these agents are designed, delivered, and deployed across different cancer subtypes. Here’s how the market is currently structured — and where it’s heading between now and 2030.

By Drug Type

• Small Molecule Inhibitors: Currently the most dominant class, these molecules—primarily SAM-competitive inhibitors—block PRMT5’s methyltransferase activity. They make up over 70% of clinical-stage assets as of 2024. Expected to remain the lead format through 2027, especially in MTAP-deleted tumors and splicing-altered cancers.

• Allosteric Inhibitors: Designed to bind outside the active site, these are gaining traction for their improved selectivity and potentially reduced toxicity. Still in early-stage development, but attractive in MYC-driven cancers and splicing-mutant gliomas.

• Protein Degraders (e.g., PROTACs): An emerging class using degradation rather than inhibition to eliminate PRMT5 protein. These are largely in preclinical pipelines but have high investor interest. By 2028, degraders may account for a growing share of trials—particularly in resistant tumor types.

In 2024, small molecules dominate with >70% market share, but by 2030, hybrid formats and degraders are expected to reshape the landscape.

 

By Application

• NSCLC (Non-Small Cell Lung Cancer): The leading solid tumor indication, accounting for ~24% of clinical trial recruitment in 2024. Focused primarily on MTAP-deleted or MYC-amplified subtypes.

• Glioblastoma & Pancreatic Cancer: High-priority targets due to splicing mutations and PRMT5 dependency. Limited treatment options make these strong candidates for early adoption.

• Mantle Cell Lymphoma, AML, MDS: In hematologic malignancies, PRMT5 is showing promise — especially in BCL-2-resistant AML and splicing-aberrant MDS. Combination strategies are being piloted with checkpoint inhibitors, BCL-2 antagonists, and PARP inhibitors.

Expect PRMT5 therapies to launch first in NSCLC and glioblastoma, then expand into hematologic malignancies via combo regimens.

 

By Route of Administration

• Oral: All clinical PRMT5 drugs as of 2024 are orally bioavailable, enabling outpatient dosing and simpler administration.

• A key advantage for precision oncology in community and outpatient settings.

• Intravenous (IV): Still exploratory, but may be useful in combination protocols where synchronized pharmacokinetics are needed (e.g., with DNA damage agents or checkpoint blockers).

Oral remains dominant through 2026+, but IV routes may grow for institutional regimens and synchronized combo trials.

 

By End User

• Academic Cancer Centers: Core sites for PRMT5 trials, with integrated diagnostics and tumor boards. These centers will lead early adoption, especially for compassionate use and real-world data collection.

• Specialty Oncology Clinics: Fast followers once approvals begin. Clinics with access to molecular profiling (NGS or liquid biopsy) will expand access beyond urban centers by 2028–2029.

• Community Hospitals: Currently limited by diagnostic capabilities, but will gradually adopt via partnerships with centralized labs and diagnostic + treatment bundles.

• Contract Research Organizations (CROs): CROs play a key operational role in biomarker-enriched trial execution, site selection, and post-approval access zone planning.

Early uptake will be driven by academic and specialty sites, but community penetration hinges on bundled diagnostics and real-world feasibility.

 

By Region

• North America: The largest market, driven by U.S.-based trials, FDA fast-tracking, and widespread MTAP testing. Expected to maintain ~50% revenue share through 2030.

• Europe: Early adoption in Germany, UK, France, and Netherlands due to strong NGS infrastructure. Slower payer adoption may delay commercial rollout.

• Asia Pacific: Fastest-growing region, led by China, South Korea, and Japan. Domestic biotechs and favorable regulatory timelines are enabling regional innovation hubs.

• Latin America, Middle East & Africa (LAMEA): Lowest penetration to date. Pockets of growth in Brazil, UAE, and South Africa via early access and trial participation, but limited mainstream adoption before 2030.

Asia Pacific is emerging as the fastest growth region, while North America leads in trial volume and commercial preparation.

 

Market Trends And Innovation Landscape

The PRMT5 targeted therapies market is evolving faster than expected — not just in terms of clinical trial progress, but in how companies are designing molecules, structuring partnerships, and stacking regimens. Several innovation trends are pushing this space beyond early discovery into full-fledged oncology strategy.

Synthetic Lethality Is Moving from Theory to Practice

Synthetic lethality is no longer just an academic buzzword — it’s the foundational thesis for PRMT5 therapy. Drug developers are now operationalizing this concept by identifying cancers that are dependent on PRMT5 due to co-deletions or mutations (e.g., MTAP loss, splicing factor mutations, or CDKN2A/B deletions ).

Rather than targeting PRMT5 broadly, these therapies are being paired with companion diagnostics that identify molecular vulnerabilities. As a result, clinical trial enrollment is increasingly biomarker-enriched — which improves response rates and lowers development risk.

One analyst noted, “This isn’t like chasing EGFR across the board. It’s more like finding a rare lock — and then making a perfect key.”

 

From Enzyme Inhibition to Degradation

Current clinical candidates mostly fall into the SAM-competitive inhibitor category — they block the methyltransferase activity of PRMT5. But this approach has limitations, particularly in off-target toxicity and intracellular competition.

Newer platforms are shifting toward protein degraders, using PROTAC or molecular glue mechanisms to knock down PRMT5 entirely. The hope? Longer-lasting effects, better tumor selectivity, and reduced systemic exposure.

Some of the most well -funded PRMT5 programs in stealth or preclinical stages are degraders — a clear signal that this may become the dominant innovation track by 2026–2027.

 

AI and Structural Biology Are Accelerating Candidate Optimization

Structure-guided drug design is critical for a target like PRMT5, where binding specificity is hard to achieve. AI-assisted platforms are now being used to:

• Optimize binding affinity without triggering off-target methylation

• Model conformational changes in mutant PRMT5 variants

• Predict resistance pathways, especially in tumors with rapid clonal evolution

Companies like Exscientia and Schrödinger are already involved in AI-driven epigenetic drug development. While they haven’t all disclosed PRMT5-specific programs, the underlying tech is being applied to this target class.

An early-stage biotech CEO shared, “We used to run 15 cycles before getting a clinical candidate. With AI and cryo -EM, we’re down to 5.”

 

Combinations Are the Real Commercial Play

Most experts agree that PRMT5 monotherapy will likely serve a niche — perhaps in MTAP-deleted sarcomas or lymphomas. The broader opportunity lies in combination regimens, particularly with:

• Checkpoint inhibitors (e.g., anti-PD-1): PRMT5 modulates immune gene expression, and early data suggests synergy in cold tumors.

• PARP inhibitors : Co-targeting DNA damage and RNA splicing pathways may be effective in resistant ovarian or pancreatic cancers.

• BCL-2 inhibitors : In AML and MDS, this combo may hit both apoptotic and epigenetic vulnerabilities.

Several trials are already using combination arms even in Phase I — a rare move that shows just how strategic PRMT5 is becoming in broader oncology portfolios.

 

Diagnostics Are the Hidden Innovation Layer

A major driver of future success will be the expansion of diagnostic infrastructure. Right now, only top-tier centers routinely test for MTAP status or splicing mutations. But diagnostic players are beginning to integrate PRMT5-relevant markers into NGS panels and liquid biopsy platforms.

This is critical. Without scalable testing, eligible patients won’t be identified — and market access will stall. Expect partnerships between biopharma and diagnostic labs to accelerate post-2025.

 

To be honest, PRMT5 innovation isn’t just about the molecule anymore. It’s about building a treatment framework that includes diagnostics, delivery models, and predictive algorithms. And that’s why investors, pharma giants, and researchers are converging around this small but strategic target.

 

Competitive Intelligence And Benchmarking

The PRMT5 targeted therapies landscape may look early-stage on paper, but behind the scenes, it’s a high-stakes race among biotech disruptors and Big Pharma incumbents. As of 2024, only a handful of clinical candidates are in the spotlight — but the strategic posturing, licensing deals, and preclinical depth suggest a coming wave of commercial rivalry. Here’s a closer look at the companies shaping the field.

Prelude Therapeutics

Prelude is arguably the most advanced biotech in the PRMT5 space. Its lead asset, PRT543, has moved through early clinical trials in solid tumors and hematologic malignancies with MTAP deletions. The company is also developing backup compounds like PRT811, optimized for brain penetration — potentially opening doors in glioblastoma.

Their edge? A focused pipeline built around PRMT5 and adjacent targets, plus a clean biomarker strategy. Investors have taken note: Prelude raised over $250 million in recent years to push deeper into combination trials.

 

Storm Therapeutics

This UK-based biotech is pioneering RNA epigenetics — and PRMT5 is central to that play. Storm Therapeutics is developing small molecules that block PRMT5-mediated RNA methylation, rather than the classic histone modifications. That gives them a slightly differentiated mechanism, with potential advantages in splicing-related cancers.

The company recently entered into research collaborations with global pharma firms, hinting at future licensing or co-development deals.

 

Merck & Co.

Yes, Merck is in the game — although it’s playing long. The company has been investing in synthetic lethality platforms and early discovery programs aimed at epigenetic modifiers. PRMT5 isn’t their lead asset, but they’ve signaled strong interest through research partnerships and biomarker discovery efforts.

Merck’s broader strategy seems to involve building a combination-ready arsenal, with PRMT5 as a potential add-on to immuno-oncology and DNA-damage inhibitor regimens.

 

Roche

Roche has emerged as a major player through partnerships and pipeline expansion. It recently inked a multi-year collaboration with a leading structural biology institute focused on PRMT5 inhibitors and degraders. This builds on its strong diagnostic capability — positioning Roche to offer companion diagnostics alongside targeted therapies, a move that could provide significant market control.

The company’s in-house development is still under wraps, but internal job postings and research patents suggest a PROTAC-based PRMT5 degrader is underway.

 

GSK

While GSK doesn’t currently have a disclosed PRMT5 inhibitor in Phase I, it’s heavily involved in adjacent methyltransferase targets and has invested in external platforms that include PRMT5. GSK’s real strength is in oncology combinations — especially with its checkpoint inhibitors and antibody-drug conjugates. PRMT5 could eventually be folded into this broader network.

Their 2023 acquisition of a biotech with splicing-related assets indicates a likely pivot toward spliceosome-driven tumor biology, making PRMT5 a strategic fit.

 

Epizyme (acquired by Ipsen)

Epizyme, before its acquisition by Ipsen, was an early mover in epigenetic oncology. While its commercial focus was EZH2, the company laid foundational IP and screening tools for PRMT5 inhibition. Post-acquisition, those assets remain in development — especially for hematologic cancers — and may resurface as part of Ipsen’s oncology expansion strategy.

 

Emerging Startups

A few stealth-stage startups are quietly gaining attention. These include:

• A Boston-based AI-drug design firm applying structure-predictive modeling to PRMT5

• A Shanghai biotech with first-in-class PRMT5 degraders already in preclinical toxicity testing

• A European spinout from an academic lab focused on PRMT5 and MYC co-dependencies

While none are public yet, several have received Series A or seed funding in the $30–50M range, which suggests they’re moving toward IND-enabling studies.

 

Regional Landscape And Adoption Outlook

The commercial outlook for PRMT5 targeted therapies is being shaped not just by clinical data, but by how different regions approach precision oncology, biomarker testing, and early access to novel therapeutics. While the U.S. currently leads in terms of trial volume and infrastructure, other regions are moving quickly to establish competitive footholds — especially where synthetic lethality and splicing-targeted oncology are gaining momentum.

North America

The United States is still the epicenter of PRMT5 innovation — home to the majority of ongoing trials, biotech innovators, and regulatory momentum. Several reasons explain this dominance:

• Broad adoption of biomarker-guided oncology, including routine testing for MTAP deletions

• The FDA’s supportive stance on orphan drug designation, fast track, and breakthrough therapy pathways — several PRMT5 programs are already under these designations

• Strong presence of specialized cancer centers like MD Anderson, Dana-Farber, and Memorial Sloan Kettering, which are leading early-phase PRMT5 combination trials

To be honest, the U.S. market is less about proving clinical need — and more about executing access models that fit small, molecularly defined patient segments.

Canada, though smaller, benefits from a centralized system that supports rare disease and early-phase oncology research. PRMT5 inhibitors will likely enter Canada closely behind the U.S., especially via expanded access and post-approval managed entry.

 

Europe

Europe has a mixed but promising outlook. Countries like Germany, the UK, France, and the Netherlands are rapidly incorporating next-generation sequencing (NGS) and splicing mutation panels into clinical workflows — making them early candidates for PRMT5 therapy rollout.

• The European Medicines Agency (EMA) has been more deliberate than the FDA in synthetic lethality approvals, but it offers clear guidance on biomarker-defined therapies

• The UK’s Cancer Research UK and Germany’s DKFZ are both engaged in academic partnerships targeting epigenetic modifiers — including PRMT5

• National health systems like NHS England have programs to fast-track rare cancer treatments, which could support PRMT5 access in MTAP-deleted sarcomas or gliomas

Challenges include variability in diagnostic infrastructure and payer hesitancy around high-cost molecular therapies for small populations. That said, Germany and the UK are expected to drive European uptake starting in 2027.

 

Asia Pacific

The Asia Pacific region is emerging as a fast-follower — and in some countries, a stealth innovator. The PRMT5 opportunity here is twofold: local clinical development and regional licensing deals.

• China is scaling up early oncology research at pace. Companies like Hengrui Pharma and BeiGene are rumored to be exploring PRMT5-related assets. China’s regulatory agency, the NMPA, has improved timelines for first-in-class therapies — meaning PRMT5 assets could launch locally faster than expected.

• South Korea and Japan are leading in biomarker infrastructure. Several large cancer centers are already screening for spliceosome mutations and MTAP deletions as part of routine panels, giving them a clear head start.

While India lacks widespread diagnostic coverage today, its growing network of molecular labs and cancer hospital chains (e.g., Tata Memorial ) could support PRMT5 adoption via global licensing partnerships.

 

Latin America, Middle East, and Africa (LAMEA)

Currently, LAMEA represents the lowest penetration zone for PRMT5 therapies — largely due to limited diagnostic access, high out-of-pocket costs, and slower regulatory frameworks. That said, pockets of opportunity exist:

• Brazil and Mexico are expanding national rare cancer treatment networks, and both countries have oncology trial sites that could host PRMT5 studies

• Saudi Arabia and the UAE have invested heavily in genomic infrastructure as part of their national health transformation programs — creating early commercial opportunities for biomarker-driven therapies

• In Africa, adoption will likely be limited to urban private hospitals or NGO-funded access programs for rare pediatric or hematologic cancers

For now, global biopharma players are unlikely to prioritize LAMEA for first-wave launches — but early access programs and compassionate use could bridge the gap.

 

End-User Dynamics And Use Case

End-user adoption of PRMT5 targeted therapies will hinge on two things: how precisely patients can be identified through molecular diagnostics, and how easily the therapies can be integrated into existing treatment regimens. Because these drugs are still in clinical development, the current end-user landscape is largely defined by trial infrastructure and biomarker capabilities — but that will shift quickly post-approval.

Let’s break down the most relevant end-user categories and what each needs from a future commercial PRMT5 product.

Academic Cancer Centers

These institutions are the beating heart of PRMT5 clinical development. Centers like Dana-Farber, MD Anderson, Memorial Sloan Kettering, and University of California San Diego are running most of the early-phase trials. They typically feature:

• Dedicated Phase I oncology units

• Advanced molecular tumor boards

• In-house genomic profiling for MTAP deletions, splicing mutations, and MYC amplification

They’ll remain critical post-approval for real-world data (RWD) collection, combination therapy pilots, and expanded access programs.

Also, these centers often co-author early publications — meaning they shape physician perception and clinical guideline adoption.

 

Specialized Oncology Clinics

In the commercial phase, adoption will likely shift to specialty oncology networks and molecularly focused private practices, particularly in the U.S. and parts of Europe.

These clinics typically handle:

• Mid-volume patient loads

• Advanced solid tumors (NSCLC, glioma, pancreatic)

• Molecular profiling via external lab partnerships

What they need from a PRMT5 product is clarity and simplicity — clear eligibility markers, defined treatment windows, and minimal drug-drug interaction complexity when used in combination.

As more liquid biopsy panels begin reporting MTAP status, these clinics could drive a significant portion of outpatient PRMT5 therapy volumes by 2028–2029.

 

Community Hospitals and General Oncology Practices

This tier will be slower to adopt PRMT5 therapies, primarily due to limited access to NGS and low familiarity with synthetic lethality approaches. However, partnerships with large diagnostic labs (e.g., Foundation Medicine, Caris, Tempus ) will help bridge the gap over time.

Vendors that provide turnkey diagnostic + treatment bundles — much like HER2 or EGFR models — will gain ground here.

 

Contract Research Organizations (CROs)

CROs are playing a larger-than-usual role in PRMT5 trial execution, particularly for global multi-center studies targeting MTAP-deleted populations. Their insights into trial site readiness, enrollment hurdles, and biomarker turnaround times will be valuable during commercialization planning.

Expect CROs to evolve into strategic partners, helping biopharma firms ma p access zones based on diagnostic penetration and site-level throughput.

 

Use Case Spotlight:

A leading cancer institute in Germany was treating a 58-year-old patient with recurrent, chemotherapy-resistant NSCLC. Genomic profiling revealed an MTAP deletion — making the patient eligible for a PRMT5-targeted therapy under a compassionate use program. The hospital collaborated with a U.S.-based biotech to obtain the drug, enrolled the patient in an off-protocol registry, and monitored response using liquid biopsy and radiologic tracking.

Within 6 weeks, the tumor burden dropped by 34%. More importantly, the patient tolerated the therapy well — no severe cytopenias , no dose delays. This real-world case reinforced both the diagnostic pathway and clinical feasibility of PRMT5 monotherapy in a highly targeted setting.

 

To be clear, not every hospital will be ready to jump into PRMT5 therapy on Day 1. But the ones that are — academic hubs, biomarker-driven clinics — will create the blueprint for broader use. And success in those early cases will dictate how fast adoption scales across the oncology landscape.

 

Recent Developments + Opportunities & Restraints

The PRMT5 targeted therapies space has moved from scientific theory to clinical reality in just a few years. As of 2024, momentum is building across trials, partnerships, and diagnostic readiness. While the pipeline is still early, recent moves from both biotech and pharma players signal a sharp uptick in confidence. Below is a snapshot of notable developments — and a look at what’s propelling (and slowing) market expansion.

Recent Developments (Last 2 Years)

• Prelude Therapeutics expanded enrollment for its PRMT5 inhibitor PRT543 in MTAP-deleted solid tumors, following positive safety signals. Combination trials with checkpoint inhibitors are now underway in the U.S.

• Storm Therapeutics signed a multi-million dollar partnership with a global pharmaceutical firm to co-develop RNA-modifying enzyme inhibitors, including preclinical-stage PRMT5 assets.

• A UC San Diego research group published preclinical findings showing that PRMT5 inhibition sensitized MYC-driven pancreatic tumors to immune checkpoint blockade — potentially a major advance for combination therapy approaches.

• Roche filed patents for a novel PROTAC-based PRMT5 degrader platform in early 2024, signaling new direction in targeted protein degradation.

• Foundation Medicine updated its NGS panel to report MTAP deletion status, enabling broader access to PRMT5-targeted screening across community oncology networks.

 

Opportunities

• Diagnostic-Driven Commercial Models:
  As more pathology labs include MTAP, CDKN2A/B, and splicing mutation testing in routine oncology panels, PRMT5 patient identification infrastructure is scaling rapidly. This paves the way for precision access programs — similar to the PARP inhibitor model.

• Combination Trials in Resistant Tumors:
  PRMT5 inhibitors may resensitize tumors resistant to chemo and immunotherapy — with NSCLC, glioblastoma, and AML showing early promise. Pairing PRMT5 with PD-1, PARP, or BCL-2 agents could unlock regulatory acceleration and broader utility.

• China and South Korea as Secondary Innovation Hubs:
  Domestic biotechs in Asia-Pacific — especially China and South Korea — are advancing homegrown PRMT5 programs supported by government grants and accelerated clinical trial timelines, reducing dependence on Western IP and licensing.

 

Restraints

• Limited Patient Pools per Indication:
  Despite prevalence in cancers like lung and pancreatic, the actual number of patients with actionable MTAP deletions or relevant splicing mutations is small — limiting monotherapy scale unless combination regimens expand eligibility.

• High Development and Biomarker Integration Costs:
  Developing PRMT5 therapies entails high R&D spend plus co-development of companion diagnostics. Early-stage biotechs may face execution risk without large pharma backing.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 412 Million
Revenue Forecast in 2030	USD 1.92 Billion
Overall Growth Rate	CAGR of 28.4% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Drug Type, Application, Route of Administration, End User, Geography
By Drug Type	Small Molecule Inhibitors, Allosteric Inhibitors, Protein Degraders
By Application	NSCLC, Glioblastoma, Pancreatic Cancer, Mantle Cell Lymphoma, AML, MDS
By Route of Administration	Oral, Intravenous
By End User	Academic Cancer Centers, Oncology Clinics, Community Hospitals, CROs
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, Japan, South Korea, Brazil, Saudi Arabia
Market Drivers	- Rise in MTAP deletion–targetable cancers - Surge in combination trial designs - Growth in diagnostic integration for PRMT5 biomarkers
Customization Option	Available upon request